Warnings Added to Immediate-Release Opioids

"We know that there is persistent abuse, addiction, overdose mortality, and risk of NOWS associated with IR opioid products," said Dr. Douglas Throckmorton, M.D., deputy center director of regulatory programs at FDA's Center for Drug Evaluation and Research. "Today, we have taken an important next step in clarifying and making more prominent the known risks of IR opioid medications."

The U.S. Food and Drug Administration is requiring safety labeling changes for immediate-release (IR) opioid pain medications, including a new boxed warning about the serious risks of misuse, abuse, addiction, overdose, and death. Its March 22 actions are part of FDA's plan to reassess its approach to opioid medications and reverse the epidemic of opioid medication abuse while still providing patients pain relief.

FDA is also requiring several additional safety labeling changes across all prescription opioid products that warn of the risk in these medications. "Opioid addiction and overdose have reached epidemic levels over the past decade, and the FDA remains steadfast in our commitment to do our part to help reverse the devastating impact of the misuse and abuse of prescription opioids," said Dr. Robert Califf, M.D., FDA's commissioner. "Today's actions are one of the largest undertakings for informing prescribers of risks across opioid products and one of many steps the FDA intends to take this year as part of our comprehensive action plan to reverse this epidemic."

The updated indication clarifies that because of the risks, IR opioids should be reserved for pain severe enough to require opioid treatment and for which alternative treatment options (non-opioid pain relievers or opioid combination products, as appropriate) are inadequate or not tolerated. The dosing information also provides clearer instructions regarding patient monitoring and drug administration, including initial dosage, dosage changes during therapy, and a warning not to abruptly stop treatment in a physically dependent patient. As part of the boxed warning on IR opioid analgesics, the FDA now requires a precaution that chronic maternal use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated using protocols developed by neonatology experts.

In 2013, the FDA required class-wide labeling changes for ER/LA opioid analgesics, including modifications to the products' indications, limitations of use, and warnings to more effectively communicate to prescribers the serious risks associated with them. FDA now is requiring similar changes to the labeling of IR opioid analgesics. "We know that there is persistent abuse, addiction, overdose mortality, and risk of NOWS associated with IR opioid products," said Dr. Douglas Throckmorton, M.D., deputy center director of regulatory programs at FDA's Center for Drug Evaluation and Research. "Today, we have taken an important next step in clarifying and making more prominent the known risks of IR opioid medications."

FDA also announced it is carefully reviewing available scientific information about potentially serious outcomes related to interactions between benzodiazepines and opioids and, once the review is finished, will take necessary actions to ensure prescribers and the public are informed of the risks involved with their use.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch in 2019

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue